Can a new oral drug take on hard-to-treat leukaemia?
Disease control
Not yet recruiting
This early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…
Phase: PHASE1 • Sponsor: Amphista Therapeutics Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC